No Association between the 20210 G/A Prothrombin Gene Mutation and Premature Coronary Artery Disease

Summary

The 20210 G/A prothrombin gene mutation is associated with an increased risk of venous thrombosis but whether there is an association of the mutation with premature coronary artery disease and acute myocardial infarction remains unclear.

To further assess the role of the G/A genotype as a risk factor for arterial vascular disease, we performed a case-control study of 644 patients aged less than 50 years with angiographically proven coronary artery disease, 402 of whom had myocardial infarction, and 679 unrelated healthy control subjects aged less than 50 years, randomly selected from the electoral roll.

The prevalence of the G/A genotype was 2.5% in patients with coronary artery disease, and 3.2% in control subjects (odds ratio 0.8; 95% confidence interval 0.35 to 1.83). The mutation was not more frequent among patients with a history of myocardial infarction (2.2%, odds ratio 0.7; 95% confidence interval 0.27 to 2.05), and there was no evidence of an interaction between the prothrombin mutation and conventional cardiovascular disease risk factors. There was no association between genotype and extent of angiographic coronary artery disease (p = 0.73).

We conclude that the 20210 G/A prothrombin gene mutation is not a major risk factor for premature coronary artery disease in our predominantly Caucasian Australian population.

• References

• 1 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.. Blood 1996; 88: 3698-703.
• 2 Ridker PM. Fibrinolytic and inflammatory markers for arterial occlusion: the evolving epidemiology of thrombosis and hemostasis.. Thromb Haemost 1997; 78: 53-9.
• 3 Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease.. Thromb Haemost 1996; 75: 767-71.
• 4 Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women.. Blood 1997; 90: 1747-50.
• 5 Arruda VR, Annichino-Bizzachi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease.. Thromb Haemost 1997; 78: 1430-3.
• 6 Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, Ardissino D, Palareti G, Bernardi F. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease.. Arterioscler Thromb Vasc Biol 1997; 17: 2418-22.
• 7 Kapur RK, Mills LA, Spitzer SG, Hultin MB. A prothrombin gene mutation is significantly associated with venous thrombosis.. Arterioscler Thromb Vasc Biol 1997; 17: 2875-9.
• 8 Watzke HH, Schuttrümpf J, Graf S, Huber K, Panzer S. Increased prevalence of a polymorphism in the gene for human prothrombin in patients with coronary heart disease.. Thromb Res 1997; 87: 521-6.
• 9 Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A.. Circulation 1998; 97: 1037-41.
• 10 Fuster V, Badimon L, Badimon JJ, Chexbro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes.. N Engl J Med 1992; 326: 242-50.
• 11 Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary artery surgery study registry).. J Am Coll Cardiol 1995; 26: 654-61.
• 12 Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, Bayliss P, Peake IR, Miller GJ. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia.. Thromb Haemost 1997; 78: 1426-9.
• 13 Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CRM. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population.. Br J Haematol 1997; 98: 353-5.
• 14 Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3’-untranslated region of the prothrombin gene.. Br J Haematol 1997; 98: 907-9.
• 15 Hillarp A, Zöller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis.. Thromb Haemost 1997; 78: 990-2.
• 16 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden.. Lancet 1995; 346: 1133-4.
• 17 van Bockxmeer F, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V.. Nature Med 1995; 1: 185.